Across TCGA pan-cancer cohorts, IGHV3-13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV3-13 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IGHV3-13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-13 expression acts as an unfavorable survival marker.
SKCM and LUAD are the cancer types where IGHV3-13 Mutation most reproducibly stratifies survival.